Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Twice Daily on Nutritional Status in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Overview

Información sobre este estudio

To evaluate the safety and effectiveness of oral nutritional therapy Serum-Derived Bovine Immunoglobulin (SBI) on nutritional status, epithelial barrier function, and mucosal expression of pivotal genes including tight junction, secretory mechanisms, tissue repair proteins and chemokines in subjects with IBS-D.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion criteria:

  1. Age 18-65y
  2. Male or non-pregnant female
  3. IBS by Rome III criteria with predominant symptom of diarrhea
  4. Baseline 14 day diary showing average of 2 days per week with >3 bowel movements per day

Exclusion criteria:

  1. Intake of medications that interfere with the study
  2. Antibiotic within prior 2 weeks and throughout study
  3. Prior abdominal surgery except appendectomy
  4. Active gastrointestinal diagnosis other than IBS
  5. History of allergy or intolerance to beef or to any ingredient in the investigational product
  6. Uncontrolled psychiatric disorders (includes significant depression or suicidal ideation), in investigator's judgment
  7. Use of tobacco products within the past six months or NSAIDs or aspirin within the past week (since they all may affect intestinal permeability)
  8. Bleeding disorders or medications that increase risk of bleeding from mucosal biopsies.
  9. For two days prior to studies, patients are instructed to avoid ingestion of artificial sweeteners such as Splenda™ (sucralose), Nutrasweet™ (aspartame), foods containing lactulose or mannitol.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Michael Camilleri, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20111483

Mayo Clinic Footer